Adverse reactions of 300 MG diethylcarbamazine, and in a combination of 400 MG albendazole, for a mass annual single dose treatment, in migrant workers in Phang Nga province

Journal of the Medical Association of Thailand

Volumn 90, Issue 3, 2007, Pages 552-563

  Yongyuth, Pisit ^a   Koyadun, Surachart ^b   Jaturabundit, Nongnuch ^c   Jariyahuttakij, Wuttisal ^a   Bhumiratana, Adisak ^d  

^a Thap Put Hospital   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c Dental Department   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Adverse drug reactions; Albendazole; Diethylcarbamazine; Myanmar migrants

Indexed keywords

ALBENDAZOLE; DIETHYLCARBAMAZINE;

ADENOLYMPHANGITIS; ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; CONVULSION; COUGHING; DECREASED APPETITE; DIARRHEA; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG TOLERABILITY; EPIDIDYMITIS; FATIGUE; FEVER; FILARIASIS; FLATULENCE; FUNICULITIS; HEADACHE; HUMAN; INCREASED APPETITE; JOINT STIFFNESS; LYMPHADENITIS; LYMPHANGITIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MALE GENITAL TRACT INFLAMMATION; MIGRANT WORKER; MONOTHERAPY; MUSCLE CRAMP; MYALGIA; NAUSEA; PAIN; PREVALENCE; RASH; SCORING SYSTEM; SCROTAL PAIN; SEIZURE; SINGLE DRUG DOSE; SKIN IRRITATION; STOMACH CRAMP; URTICARIA; VOMITING; WHEEZING; WUCHERERIA BANCROFTI; XEROSTOMIA;

ADOLESCENT; ADULT; ALBENDAZOLE; ANTHELMINTICS; DIETHYLCARBAMAZINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FILARICIDES; HUMANS; MALE; MIDDLE AGED; THAILAND; TRANSIENTS AND MIGRANTS;

EID: 33947242757     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bureau of Public Health Policy and Plan, Office of the Permanent Secretary of Public Health. Health situation in foreign migrant workers, by fiscal year 2001. Nonthaburi: Health Education Division, Bureau of Public Health Policy and Plan, OPSPH; 2001.
2. Workshop on policy and strategic approaches to foreign migrant worker health held at Chao Phraya Park Hotel, Bangkok, Thailand, 11-12 March 2003.
3. Yongyuth P, Koyadun S, Jaturabundit N, Sampuch A, Bhumiratana A. Efficacy of a single-dose treatment with 300 mg diethylcarbamazine and a combination of 400 mg albendazole in reduction of Wuchereria bancrofti antigenemia and concomitant geohelminths in Myanmar migrants in Southern Thailand. J Med Assoc Thai 2006; 89: 1237-48.
4. Ottesen EA, Duke BO, Karam M, Behbehani K. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 1997; 75: 491-503.
5. Ottesen EA, Ismail MM, Horton J. The role of albendazole in programmes to eliminate lymphatic filariasis. Parasitol Today 1999; 15: 382-6.
6. Horton J, Witt C, Ottesen EA, Lazdins JK, Addiss DG, Awadzi K, et al. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology 2000; 121 Suppl: S147-S160.
7. World Health Organization. Preparing and implementing a national plan to eliminate lymphatic filariasis (in countries where onchocerciasis is not co-endemic). WHO/CDS/CPE/CEE/2000.15. Geneva: WHO; 2002.
8. World Health Organization. Lymphatic Filariasis Elimination Programme: Training module for drug distributors in countries where lymphatic filariasis is not co-endemic with onchocerciasis. WHO/CDS/CPE/CEE/2001.22 Part I. Distribution: General: Learner's guide. Geneva: WHO; 2001.
9. Molyneux DH, Bradley M, Hoerauf A, Kyelem D, Taylor MJ. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol 2003; 19: 516-22.
10. Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology 2000; 121(Suppl): S113-32.
11. Pani S, Subramanyam RG, Das L, Vanamail P, Hoti S, Ramesh J, et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co-administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital-based study. Filaria J 2002; 1: 1.
12. Shenoy RK, Suma TK, John A, Arun SR, Kumaraswami V, Fleckenstein LL, et al. The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole. Ann Trop Med Parasitol 2002; 96: 603-14.
13. McLaughlin SI, Radday J, Michel MC, Addiss DG, Beach MJ, Lammie PJ, et al. Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000. Am J Trop Med Hyg 2003; 68: 568-73.
14. El Setouhy M, Ramzy RM, Ahmed ES, Kandil AM, Hussain O, Farid HA, et al. A randomized clinical trial comparing single- and multi-dose combination therapy with diethylcarbamazine and albendazole for treatment of bancroftian filariasis. Am J Trop Med Hyg 2004; 70: 191-6.
15. Koyadun S, Bhumiratana A, Prikchu P. Wuchereria bancrofti antigenemia clearance among Myanmar migrants after biannual mass treatments with diethylcarbamazine, 300 mg oral-dose FILADEC tablet, in Southern Thailand. Southeast Asian J Trop Med Public Health 2003; 34: 758-67.
16. Bhumiratana A, Siriaut C, Koyadun S, Satitvipawee P. Evaluation of a single oral dose of diethylcarbamazine 300 mg as provocative test and simultaneous treatment in Myanmar migrant workers with Wuchereria bancrofti infection in Thailand. Southeast Asian J Trop Med Public Health 2004; 35: 591-8.
17. Bhumiratana A, Koyadun S, Srisuphanunt M, Satitvipawee P, Limpairojn N, Gaewchaiyo G. Border and imported bancroftian filariases: baseline seroprevalence in sentinel populations exposed to infections with Wuchereria bancrofti and concomitant HIV at the start of diethylcarbamazine mass treatment in Thailand. Southeast Asian J Trop Med Public Health 2005; 36: 390-407.
18. Siriaut C, Bhumiratana A, Koyadun S, Anurat K, Satitvipawee P. Short-term effects of treatment with 300 mg oral-dose diethylcarbamazine on nocturnally periodic Wuchereria bancrofti microfilaremia and antigenemia. Southeast Asian J Trop Med Public Health 2005; 36: 832-40.
19. Haarbrink M, Terhell AJ, Abadi GK, Mitsui Y, Yazdanbakhsh M. Adverse reactions following diethylcarbamazine (DEC) intake in 'endemic normals', microfilaraemics and elephantiasis patients. Trans R Soc Trop Med Hyg 1999; 93: 91-6.
20. Turner PF, Rockett KA, Ottesen EA, Francis H, Awadzi K, Clark IA. Interleukin-6 and tumor necrosis factor in the pathogenesis of adverse reactions after treatment of lymphatic filariasis and onchocerciasis. J Infect Dis 1994; 169: 1071-5.
21. Jaturabundit N, Yongyuth P, Koyadun S, Bhumiratana A. Adverse general health outcomes in Myanmar migrant workers in parawood production cluster of Phangnga Province. J Health Sci. 2006; 15: 594-605.
22. Koyadun S, Bhumiratana A. Surveillance of imported bancroftian filariasis after two-year multiple-dose diethylcarbamazine treatment. Southeast Asian J Trop Med Public Health 2005; 36: 822-31.
23. World Health Organization. Global programme to eliminate lymphatic filariasis. Programme activities 1999. An informal report. WHO/CDS/CPE/CEE/FIL. Available from: http://www.who.int/ctd/filariasis/docs/PELF99.pdf]
24. Communicable Disease Control Department, Ministry of Public Health. Communicable disease control in Thailand 2000. Bangkok: Express Transportation Organization; 2001: 46-8.